Taming glioblastoma by targeting angiogenesis: 3 Years later

Journal of Clinical Oncology

Volumn 29, Issue 2, 2011, Pages 124-126

  Wong, Eric T ^a   Brem, Steven ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD11B ANTIGEN; HEPARIN; SUNITINIB; TEMOZOLOMIDE; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; BLEEDING; BRAIN HEMORRHAGE; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; COLORECTAL CANCER; CRANIOTOMY; DRUG EFFICACY; EDITORIAL; GLIOBLASTOMA; HUMAN; LIVER METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SECONDARY INFECTION; THROMBOEMBOLISM; WOUND DEHISCENCE; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; DACARBAZINE; GLIOBLASTOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 79951971900     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.5282     Document Type: Editorial

References (28)

1. Vredenburgh JJ, Desjardins A, Herndon JE, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729, 2007 (Pubitemid 350086473)
2. 18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 25:4714-4721, 2007
3. National Cancer Institute: FDA approval for bevacizumab. http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab
4. Lai A, Tran A, Nghiemphu PL, et al: Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29:142-148, 2011
5. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466, 2009
6. Galanis E, Buckner JC: Enzastaurin in the treatment of recurrent glioblastoma: A promise that did not materialize. J Clin Oncol 28:1097-1098, 2010
7. Friedman HS, Prados MD, Wen PY, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740, 2009
8. Kreisl TN, Kim L, Moore K, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009
9. Wick W, Weller M, van den Bent M, et al: Bevacizumab and recurrent malignant gliomas: A European perspective. J Clin Oncol 28:e188-e192, 2010
10. Tonnesen MG, Feng X, Clark RAF: Angiogenesis in wound healing. J Investig Dermatol Sym Proc 5:40-46, 2000 (Pubitemid 32044088)
11. Dvorak HF: Tumors: Wounds that do not heal. N Engl J Med 315:1650-1659, 1986
12. Gruenberger B, Tamandl D, Schueller J, et al: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26:1830-1835, 2008
13. Scappaticci FA, Fehrenbacher L, Cartwright T, et al: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173-180, 2005 (Pubitemid 41254420)
14. Raabe A, Gerlach R, Zimmermann M, et al: The risk of haemorrhage associated with early postoperative heparin administration after intracranial surgery. Acta Neurochir 143:1-7, 2001
15. Young RF, Lawner PM: Perioperative antibiotic prophylaxis for prevention of postoperative neurosurgical infections: A randomized clinical trial. J Neurosurg 66:701-705, 1987 (Pubitemid 17072988)
16. Stark-Vance V: Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-Oncol 7:369, 2005
17. Wong ET, Gautam S, Malchow C, et al: Bevacizumab for recurrent glioblastoma multiforme: A meta-analysis. J Natl Compr Canc Netw (in press)
18. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
19. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 22:2184-2191, 2004 (Pubitemid 41095154)
20. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, and anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003 (Pubitemid 36910021)
21. Cobleigh MA, Langmuir VK, Sledge GW, et al: A phase I/II dose-escalation trial of bevacizumab in previously treated breast cancer. Semin Oncol 30:117-124, 2003 (Pubitemid 37433402)
22. De Groot JF, Piao Y: Anti-VEGF but not VEGF receptor inhibitor therapy prolongs survival and blocks myeloid cell recruitment to orthotopic glioblastoma. Proc Am Assoc Cancer Res 51:553, 2010 (abstr 2279)
23. Scott BJ, Quant EC, McNamara MB, et al: Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro-Oncology 12:603-607, 2010
24. Levin VA, Crafts DC, Norman DM, et al: Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg 47:329-335, 1977 (Pubitemid 8170121)
25. Macdonald DR, Casino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990 (Pubitemid 20195640)
26. Wen PY, Macdonald DR, Reardon DA, et al: Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol 28:1963-1972, 2010
27. Norden AD, Young GS, Setayesh K, et al: Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787, 2008
28. Rubenstein JL, Kim J, Ozawa, et al: Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306-314, 2008